Jump to content

Cabozantinib - COMET-2 Clinical Trial

Paul Edwards

Recommended Posts

Thanks to Russ Wilson for pointing out that a clinical trial of Cabozantinib is currently recruiting in Queensland, New South Wales, Victoria and Western Australia for men with metastatic hormone-refractory prostate cancer who have had chemotherapy.


Cabozantinib (marketed under the tradename Cometriq, formerly known as XL184) has been shown to reduce tumor growth, metastasis and angiogenesis. 


It was approved by the U.S. FDA in November 2012 for the treatment of medullary thyroid cancer.  It is currently undergoing clinical trials for the treatment of prostate, ovarian, brain, melanoma, breast, non-small cell lung, pancreatic, hepatocellular and kidney cancers.


Whilst previous clinical trials on men with metastatic, castration-resistant prostate cancer have shown a significant reduction in bone-related pain and other improvements in quality of life, a number of serious potential adverse effects have been observed.


The clinical trial which is recruiting in Australia is the Study of Cabozantinib Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer (COMET-2)


Click this link for more details.


There are currently clinical trials in the US looking at the use of Cabozantinib for prostate cancer before chemotherapy, either in combination with abiraterone or with hormone therapy.

Link to comment
Share on other sites


This topic is now archived and is closed to further replies.

  • Create New...